HOME >> BIOLOGY >> NEWS
International study findings link acne-like rash to effectiveness of new targeted cancer treatment

Geneva, Switzerland: Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment cetuximab has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

Professor Eric Van Cutsem told a news briefing today (Thursday 30 September) at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics that a trial, conducted in Belgium and the USA, had demonstrated that the more severe the rash the better the patients' tumours had responded to the treatment and the longer was their median survival.

Professor Van Cutsem, who is head of the Digestive Oncology Unit and Professor of Medicine at University Hospital Gasthuisberg in Leuven, said 346 patients with advanced colorectal cancer were treated in the study in Leuven and other Belgian and U.S. centres.

All the patients had metastatic cancer and had failed to respond to at least two prior chemotherapy regimens, although all still had a reasonable quality of life, either being fully active or at least still able to carry out light work.

Cetuximab, also known as Erbitux, is a new targeted treatment a monoclonal antibody designed to home in selectively on a protein called the epidermal growth factor (EGFR). EGFR is found on the surface of some cells and plays a role in regulating cell growth. Cetuximab interferes with the growth of cancer cells by binding to EGFR. It is approved by the Food and Drug Administration in the USA for use with the cancer drug irinotecan for colorectal cancer that has failed other treatments. It is also the first monoclonal antibody targeting EGFR to have gained marketing authorisation in Europe and is now being evaluated in first-line treatment of colorectal cancer, with promising results.

Professor Van Cutsem said that the acne-like rash was also a side effect of other EGFR inhibitors but it was not
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2

Related biology news :

1. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
2. ConocoPhillips & Conservation International launch Biodiversity Action Plan in Venezuela
3. A room with a view for the International Space Station: Completion of the cupola observation module
4. International symposium on nutritional genomics
5. First International Scientific Conference on Childhood Leukaemia
6. 1st International Conference on Cell Therapy for Cardiovascular Disease
7. International research conferences at the Villa Vigoni
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. STN International launches Derwent World Patents Index First View
10. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
11. International critical care doctors release first-ever guidelines for sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2018)... ... August 16, 2018 , ... With increasing safety requirements, and ... research projects, are presenting multiple challenges. To be successful in such a competitive environment, ... different aspects of the multiple tasks needed to develop a new drug or to ...
(Date:8/14/2018)... ... 2018 , ... Career fairs provide an ideal setting for ... at once. However, healthcare professionals often have hectic schedules with little spare time ... providers who wish to explore opportunities and learn about multiple employers from the ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... and commercialization, is announcing the keynote for their NAVIGATE2018 conference. , ... as keynote speaker for NAVIGATE2018 , Cognition’s annual user conference. An experienced ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... July 25, 2018 , ... ... its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery ... Officer. Additionally, the company announced the appointment of Jeff Caron to the newly ...
(Date:7/25/2018)... ... 2018 , ... John McDonald, CEO of ClearObject , ... India Business Council (IIBC), an advocacy group to strengthen economic ties between Indiana ... McDonald joins an impressive roster of local and national business leaders from organizations ...
(Date:7/24/2018)... Texas (PRWEB) , ... July 24, 2018 , ... Boval ... to support blood bank reagent suppliers. In Boval’s early days most of the ... were added to produce BSA for diagnostic purposes after gel cards changed that market ...
(Date:7/22/2018)... ... 19, 2018 , ... Mitotech S.A, a Luxembourg based clinical ... 3 clinical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will ... towards the first Phase 3 study starting as early as Fall 2018. ...
Breaking Biology Technology:
Cached News: